News and Events
Andreas Hagen Røssevold Ph.D. defensehe
On February 9th, Andreas Hagen Røssevold triumphantly completed his Ph.D. defense on "Immunotherapy and immunological biomarkers in breast cancer" at the OUH. For more details on his groundbreaking research, read his recent publications on @NatureMedicine and @jitcancer.
The Journal for ImmunoTherapy of Cancer
We are happy to share that our clinical trial ICON has been published in the Journal for ImmunoTherapy of Cancer. Thanks to the patients, collaborators, and funders (BMS, Health Region South East, Pink Ribbon/Norwegian Cancer Society).
The trial was among the first to investigate the use of immune checkpoint inhibitors in metastatic HRpos HER2neg breast cancer, concomitant with or after immunostimulating chemotherapy.
Norwegian Society of Immunology 2023 Research Priz
We are grateful to the Norwegian Society of Immunology for acknowledging our ALICE-article (Nat Med. Dec 2022; doi: 10.1038/s41591-022-02126-1) with the NSI 2023 Research Prize. The ALICE study was the first to show clinical benefit from the addition of immunotherapy to chemotherapy in metastatic breast cancer. This finding supported the study rationale of making "cold" tumors responsive to immune checkpoint blockade by using immunomodulatory chemotherapy. The study was supported by the Norwegian Cancer Society/Pink Ribbon, Heath Region South East, and Roche. Special thanks to the ALICE team, all study sites, and most of all to the patients, some of whom traveled by interconnecting flights every fortnight, even during COVID-19 restrictions.
(+) 16 millioner til kreftforskere
220 million NOK for cancer research! 2023
We are honored and grateful to the Cancer Society & Pink Ribbon for awarding their Open Call Grant to our project “Personalised Immunotherapy for Treatment Refractory Metastatic Breast Cancer”. Special thanks to everyone supporting the Cancer Society – we look forward to getting on with the work!
Interview with Dr. Kyte at San Antonio Breast Cancer Symposium (SABCS) 2022
Here Dr. Jon Amund Kyte is talking about CAR-T therapy for solid tumors, Immunotherapy in breast cancer, and clinical trials.
Nature Medicine
In patients with metastatic triple-negative #BreastCancer, atezolizumab + anthracycline-based chemotherapy improves progression-free survival, including in PD-L1 negative disease.
@andreashr @GroupKyte @AmundJon @Oslounivsykehus @UniOslo_MED
Oppløftende prøvemetode mot brystkreft : – Ville ikke stått her uten den
Guri de Lange er en av 68 deltakere i pasientstudien til kreftforsker Jon Amund Kyte.
FOTO: LASR HÅKON PEDERSEN / NRK
Stort framskritt i norsk brystkreftforskning
Generalsekretær i Kreftforeningen, Ingrid Stenstadvold Ross (t.v.), i samtale med Guri de Lange, Andreas Røsseland Hage og Jon Amund Kyte.
Foto: Hanne Marie Molde
Data from the ALICE trial published in Nature Medicine
The randomized, placebo-controlled ALICE trial investigated the effect of treating metastatic triple-negative breast cancer patients with a combination of the immune checkpoint inhibitor atezolizumab and chemotherapy. Conclusions from this trial, led by Jon Amund Kyte at Oslo University Hospital (OUH), have now been published in Nature Medicine in an article titled “Atezolizumab plus anthracyclin-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase IIb ALICE trial”.
Guri de Lange (tv) thanks the researchers Andreas Hagen Røssevold and Jon Amund Kyte for allowing her to take part in the ALICE study and is thus alive and well today - four years after she relapsed. Photo: Hanne Marie Molde
https://www.matrix-fkb.no/news
Public Defence: Cand.med Elin Aamdal
will be defending the thesis: Click here
“Treating metastatic melanoma with ipilimumab – Clinical activity, health-related quality of life and combination with a telomerase peptide vaccine”
Trial Lecture
“Prevention and early detection strategies for melanoma”
Time and place: June 22, 2022 10:15 AM, Auditorium, Research building (K-building), The Norwegian Radium Hospital
Adjudication Committee
First opponent: Lecturer Lars Ny, Sahlgrenska University Hospital
Second opponent: Professor Ingvild Vistad, University of Bergen
Third member and chair of the evaluation committee: Adjunct Professor Knut Jørgen Labori, University of Oslo
Chair of defence
Professor Ludvig A. Munthe, Faculty of Medicine, University of Oslo
Principal supervisor
Jon Amund Kyte, overlege dr.med., Seksjonsleder, Seksjon for utprøvende kreftbehandling, Forskningsgruppeleder, Seksjon for kreftimmunologi
Interviews with Pharma Boardroom
Oncologist Jon Amund Kyte shares some of the groundbreaking immunotherapy research that he and his team are conducting at Oslo University Hospital.
Webinar: Want to know more about breast cancer research?